Loading...
•
Jun 30, 2021
Reviva Q2 2021 Earnings Report
Reported financial results for the second quarter of 2021 and summarized recent business highlights.
Key Takeaways
Reviva Pharmaceuticals reported a net loss of $2.6 million for the second quarter of 2021. The company's cash and cash equivalents totaled $35.8 million as of June 30, 2021. They closed an underwritten public offering of common stock and warrants resulting in gross proceeds of $34.5 million.
Closed underwritten public offering of common stock and warrants resulting in gross proceeds of $34.5 million.
Expected to initiate pivotal Phase 3 clinical trial in Schizophrenia in Q4’21.
$35.8 Million in Cash as of June 30, 2021
Added to Russell Microcap® Index
Forward Guidance
Reviva believes that based on the current operating plan and financial resources, the Company’s cash and cash equivalents at the quarter end June 30, 2021 will be sufficient to cover general operating expenses into the second half of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...